by Curely Essentials
Purchase Type
About this medication
Mounjaro (tirzepatide) is a first-in-class dual GIP and GLP-1 receptor agonist approved for chronic weight management. It works by mimicking two natural incretin hormones (GIP and GLP-1), reducing appetite, slowing gastric emptying, and improving blood sugar control. Each pre-filled KwikPen delivers a single weekly dose subcutaneously. Treatment starts at 2.5mg for 4 weeks, then increases in 2.5mg steps every 4 weeks until the maintenance dose (5mg–15mg) is reached. Clinical trials showed average weight loss of 15–22.5% of body weight over 72 weeks.
Tirzepatide, sold under the brand name Mounjaro, is a dual GIP/GLP-1 receptor agonist used for weight management. It is the first medicine to activate both the GIP and GLP-1 hormone receptors, which play a key role in regulating appetite and blood sugar levels.
Administered as a once-weekly subcutaneous injection, Mounjaro has shown significant weight loss results in clinical trials, with patients losing an average of 15-20% of their body weight over 72 weeks.
Treatment starts at 2.5mg weekly for 4 weeks, then increases to 5mg weekly. Further dose increases (7.5mg, 10mg, 12.5mg, up to 15mg) may be made at 4-week intervals based on your response and tolerability.
Your prescriber will create a personalised treatment plan. Regular check-ins monitor your progress, side effects, and overall health to ensure the treatment remains safe and effective for you.
Store Mounjaro pens in the refrigerator (2°C to 8°C). Do not freeze. Once removed from the fridge, the pen can be kept at room temperature (up to 30°C) for up to 21 days.
Each pen is for single use only. Rotate injection sites between the abdomen, thigh, and upper arm. Do not inject into areas that are tender, bruised, or scarred.
Based on your health history, BMI and personal goals, we'll recommend the one that's right for you.
Mounjaro (tirzepatide) is a once-weekly injectable prescription medicine for weight management in adults with obesity or overweight.
Most patients begin to notice reduced appetite within the first 2-4 weeks. Measurable weight loss typically becomes apparent within 4-8 weeks. The most significant results are usually seen between months 3 and 12 of treatment. Individual results vary based on adherence, diet, exercise, and starting weight.
